[Tickers Inside] 7 Solid Gainers Over the Last 5 Sessions

This is a must read [View it in your browser.]( [ws_editorsdesk.png] --------------------------------------------------------------- [Biden Executive Order 14017 Potentially Sending Lithium Stocks Skyrocketing]( How Order 14017 Could Send This Company Skyrocketing]( --------------------------------------------------------------- July 6, 2022 From the desk of the Editor (Five Day Gainers Report) Dear Reader, We just identified 7 Five Day Gainers of all US Exchanges. If you are interested in any of these companies, we encourage you to do your own research and due diligence. Keep reading to see what we just uncovered... --------------------------------------------------------------- [The U.S. Solution to China's Copper Grab]( consumes 54% of the world's copper. Yet China mines only 8% of its copper needs, while plundering Africa, Latin America and South America for copper. The U.S. is left scrambling for new copper sources. But there's a North American copper sweet spot overlooked by China – for now. [Find Out Where This Copper Hotspot Is and How You Can Benefit]( --------------------------------------------------------------- [Trevi Therapeutics, TRVI]( Recent Analyst Action: Serge Belanger, analyst at Needham, reiterates coverage on [Trevi Therapeutics (TRVI)]( the Healthcare sector with a Buy rating and a price target of $10 (1 week ago). - Recent Price: $3.53 - Average Analyst Price Target: $10.00 (183.29%) - Market Cap: $129.21M [TipRanks.com]( also reports that [Trevi Therapeutics]( has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $10.00. The target pricing ranges from a high forecast of $10.00 down to a low forecast of $10.00. [Trevi Therapeutics (TRVI)]( last closing price was $3.53 which would put the average price target at $10.00. Here are 3rd party ratings for [TRVI]( - TipRanks.com: Strong Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 31% (76 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [America's Next Billion-Dollar Startup Is Waiting to Be Discovered]( next Etsy, Clubhouse, and Roku are out there, and we’re assembling a team of rockstar angel investors to find them. But we can’t do it without your help! [Join us here.]( --------------------------------------------------------------- [Beyond Air, XAIR]( Recent Analyst Action: Scott Henry, analyst at Roth Capital, reiterates coverage on [Beyond Air (XAIR)]( the Technology sector with a Buy rating and a price target of $15 (6 days ago). - Recent Price: $9.61 - Average Analyst Price Target: $17.75 (84.70%) - Market Cap: $252.37M [TipRanks.com]( also reports that [Beyond Air]( has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $17.75. The target pricing ranges from a high forecast of $23.00 down to a low forecast of $13.00. [Beyond Air (XAIR)]( last closing price was $9.61 which would put the average price target at $17.75. Here are 3rd party ratings for [XAIR]( - TipRanks.com: Strong Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Hold, Top 31% (76 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- [Atara Biotherapeutics, ATRA]( Recent Analyst Action: Salim Syed, analyst at Mizuho Securities, reiterates coverage on [Atara Biotherapeutics (ATRA)]( the Healthcare sector with a Buy rating and a price target of $39 (1 week ago). - Recent Price: $9.08 - Average Analyst Price Target: $19.20 (111.45%) - Market Cap: $815.43M [TipRanks.com]( also reports that [Atara Biotherapeutics]( has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $19.20. The target pricing ranges from a high forecast of $39.00 down to a low forecast of $4.00. [Atara Biotherapeutics (ATRA)]( last closing price was $9.08 which would put the average price target at $19.20. Here are 3rd party ratings for [ATRA]( - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Hold, Top 31% (76 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [FREE Pick for the Upcoming "ITL Boom!"]( #1 Ranked Bloomberg Economist Andrew Zatlin declares an historic event is rapidly approaching… Something he calls an “ITL Boom.” According to Andrew, ITL Booms are incredibly rare, happening just once every 33 years on average. And this next ITL Boom could be the LAST one you’ll ever see! The past two ITL Booms have helped create unimaginable fortunes… [Click here now to get the name and ticker (for FREE) so you can potentially make 500% or more as this FINAL ITL BOOM takes off!]( --------------------------------------------------------------- [Olink Holding, OLK]( Recent Analyst Action: Tejas Savant, analyst at Morgan Stanley, reiterates coverage on [Olink Holding (OLK)]( the Healthcare sector with a Hold rating and a price target of $15 (1 month ago). - Recent Price: $18.04 - Average Analyst Price Target: $18.33 (1.61%) - Market Cap: $1.93B [TipRanks.com]( also reports that [Olink Holding]( has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $18.33. The target pricing ranges from a high forecast of $20.00 down to a low forecast of $15.00. [Olink Holding (OLK)]( last closing price was $18.04 which would put the average price target at $18.33. Here are 3rd party ratings for [OLK]( - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Buy, Bottom 44% (139 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- [Revolution Medicines, RVMD]( Recent Analyst Action: Jonathan Chang, analyst at SVB Securities, reiterates coverage on [Revolution Medicines (RVMD)]( the Healthcare sector with a Buy rating (1 month ago). - Recent Price: $23.68 - Average Analyst Price Target: $29.67 (25.30%) - Market Cap: $1.72B [TipRanks.com]( also reports that [Revolution Medicines]( has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $29.67. The target pricing ranges from a high forecast of $40.00 down to a low forecast of $24.00. [Revolution Medicines (RVMD)]( last closing price was $23.68 which would put the average price target at $29.67. Here are 3rd party ratings for [RVMD]( - TipRanks.com: Strong Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Hold, Top 37% (91 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Volatility remains elevated, but is more trouble ahead?]( consumer price increases showing no signs of slowing down, is the U.S. economy heading for another economic meltdown? Warning lights are appearing on economists' radar screens. Keith Kaplan, CEO of TradeSmith, has prepared a new presentation that identifies fundamental trends that may lead to the next crash. [Click here to watch this exclusive presentation.]( --------------------------------------------------------------- [Cincor Pharma, CINC]( Recent Analyst Action: Dennis Ding, analyst at Jefferies, reiterates coverage on [Cincor Pharma (CINC)]( the Healthcare sector with a Buy rating and a price target of $30 (3 weeks ago). - Recent Price: $20.44 - Average Analyst Price Target: $30.00 (46.77%) - Market Cap: $770.41M [TipRanks.com]( also reports that [Cincor Pharma]( has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $30.00. The target pricing ranges from a high forecast of $30.00 down to a low forecast of $30.00. [Cincor Pharma (CINC)]( last closing price was $20.44 which would put the average price target at $30.00. Here are 3rd party ratings for [CINC]( - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: n/a - Zacks.com: Hold, Top 31% (76 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- [BridgeBio Pharma, BBIO]( Recent Analyst Action: Geoff Meacham, analyst at Bank of America Securities, reiterates coverage on [BridgeBio Pharma (BBIO)]( the Healthcare sector with a Buy rating and a price target of $13 (1 week ago). - Recent Price: $11.29 - Average Analyst Price Target: $21.20 (87.78%) - Market Cap: $1.59B [TipRanks.com]( also reports that [BridgeBio Pharma]( has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $21.20. The target pricing ranges from a high forecast of $27.00 down to a low forecast of $13.00. [BridgeBio Pharma (BBIO)]( last closing price was $11.29 which would put the average price target at $21.20. Here are 3rd party ratings for [BBIO]( - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Hold, Top 37% (91 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Copper More Critical than Lithium?]( may have grabbed the headlines as a key material in building electric vehicles (EVs). But so is copper. And copper's importance in the new green economy goes far beyond EVs. Copper is critical in building wind turbines and solar panels. It's key to power lines and upgrading the national grid. Analysts say we're facing a 10-million-ton shortfall if new copper mines are not found. [See How You Can Benefit From New Copper Discoveries.]( --------------------------------------------------------------- And there you have it--7 Five Day Gainers. Sincerely, Editor, FinancialMarketMovers.com FinancialMarketMovers.com | PO Box 407, Mt. Mourne, NC 28123 This is email was sent to {EMAIL} as part of your free newsletter subscription, [click here to unsubscribe](. Copyright © 2021 FinancialMarketMovers.com All rights reserved. This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.